RA0160

antibody from Oursmab

Targeting: CSF2RB betaGMR, CD131, IL3RB, IL5RB

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0160

Provider

Oursmab

Product name

Trabikibart (Biosimilar Reference Antibody) (CSF2RB)

Antibody type

Monoclonal

Description

Trabikibart (CSL311) is a fully human IgG4 kappa monoclonal antibody targeting the common beta chain (¦Âc) of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5) receptors (also known as CSF2RB). It binds to ¦Âc to block signaling by all three cytokines, thereby suppressing inflammation and myeloid cell activation. It is being developed for the treatment of severe asthma, chronic obstructive pulmonary disease (COPD), and other eosinophilic or neutrophilic inflammatory diseases.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Trabikibart (Biosimilar Reference Antibody) (CSF2RB)-RA0160-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.